Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease

Table 1

The characteristics of 58 patients in LAM-C arm and 54 patients in LdT-R arm.

	LAM-C	LdT-R	p
Age (years)	59 (53–63) [39–74]	59 (51–64) [40–75]	0.903
(Q1, Q3) [range]
Gender (male, %)	54 (93.1%)	44 (81.5%)	0.116
Allograft
Deceased	13 (22.4%)	22 (40.7%)	0.059
Living	45 (77.6%)	32 (59.3%)
Time after transplantation (months)	59.4 (36.0–89.4) [67–165.2]	47.0 (28.1–74.6) [8.1–186.8]	0.182
AST (u/L)	23.5 (19–33.5) [2–106]	20.5 (18–25.5) [13–111]	0.075
ALT (u/L)	22.5 (14–38) [7–105]	18 (12–27) [9–70]	0.035
Tacrolimus
Doses (mg)			0.419
Trough level(ng/ml)			0.588
Renal function			0.960
Stage II	33 (56.9%)	32 (59.3%)
Stage III	23 (39.7%)	20 (37.0%)
Stage IV	2 (3.4%)	2 (3.7%)

(Q1, Q3): interquartile.